Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/93758
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleEfficacy And Tolerability Of Vigabatrin In West Syndrome [avaliaçao Da Eficácia E Tolerabilidade Da Vigabatrina Na Síndrome De West]pt_BR
dc.contributor.authorMoraes M.H.P.pt_BR
dc.contributor.authorMontenegro M.A.pt_BR
dc.contributor.authorFranzon R.C.pt_BR
dc.contributor.authorAvila J.O.pt_BR
dc.contributor.authorGuerreiro M.M.pt_BR
unicamp.authorMoraes, M.H.P., Departamento de Neurologia, Faculdade de Ciências Médicas, (FCM), Universidade Estudual de Campinas (UNICAMP), Campinas SP, Brazilpt_BR
unicamp.authorMontenegro, M.A., Departamento de Neurologia, Faculdade de Ciências Médicas, (FCM), Universidade Estudual de Campinas (UNICAMP), Campinas SP, Brazilpt_BR
unicamp.authorFranzon, R.C., Departamento de Neurologia, Faculdade de Ciências Médicas, (FCM), Universidade Estudual de Campinas (UNICAMP), Campinas SP, Brazilpt_BR
unicamp.authorÁvila, J.O., Departamento de Neurologia, Faculdade de Ciências Médicas, (FCM), Universidade Estudual de Campinas (UNICAMP), Campinas SP, Brazilpt_BR
unicamp.authorGuerreiro, M.M., Departamento de Neurologia, Faculdade de Ciências Médicas, (FCM), Universidade Estudual de Campinas (UNICAMP), Campinas SP, Brazil, Departamento de Neurologia, FCM/UNICAMP, Caixa Postal 6111, 13083-970 Campinas SP, Brazilpt_BR
dc.description.abstractWest syndrome (WS) is a severe epileptic encephalopathy of childhood, characterized by spasms, developmental deterioration and hipsarhythymia. Objective: To evaluate the safety and efficacy of vigabatrin (VGB) in the treatment of WS. Method: We evaluated every patient diagnosed with WS seen at the pediatric epilepsy clinic and exposed to VGB. Patients were interviewed according to a semistructured questionnaire and we analyzed gender, age, etiology (cryptogenic or symptomatic), associated diseases, age of seizure onset, neuroimaging findings, EEG prior and after VGB, use of other antiepileptic drugs, time for seizure control, electroretinogram, visual complaints, adverse events and family history of epilepsy. Results: Twenty-three patients were evaluated, 16 boys, ages ranging from 1.25 years to 11.5 years (mean=5y3m). Sixteen (69.5%) patients were seizure free, five (22%) had partial seizure control and in two (8.5%) there was no improvement. Only one patient presented gabaergic retinopathy. Six (26%) patients presented adverse events: somnolence, aggressivity or retinopathy. Patients with seizure onset after 6 months of age presented better results after VGB introduction (p<0.05). There was no difference in seizure control according to duration of epilepsy before VGB treatment or etiology of the seizures (p>0.05). After VGB, no patient presented hipsarrhythymia and 50% had a normal EEG. Conclusion: Although VGB may be associated with serious adverse events such as gabaergic retinopathy, our results show that it should be considered in the treatment of WS.en
dc.relation.ispartofArquivos de Neuro-Psiquiatriapt_BR
dc.date.issued2005pt_BR
dc.identifier.citationArquivos De Neuro-psiquiatria. , v. 63, n. 2 B, p. 469 - 473, 2005.pt_BR
dc.language.isoptpt_BR
dc.description.volume63pt_BR
dc.description.issuenumber2 Bpt_BR
dc.description.firstpage469pt_BR
dc.description.lastpage473pt_BR
dc.rightsabertopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn0004282Xpt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-21744437588&partnerID=40&md5=e378bf0be8f6404a42691d7de296e97dpt_BR
dc.date.available2015-06-26T14:09:17Z
dc.date.available2015-11-26T14:09:09Z-
dc.date.accessioned2015-06-26T14:09:17Z
dc.date.accessioned2015-11-26T14:09:09Z-
dc.description.provenanceMade available in DSpace on 2015-06-26T14:09:17Z (GMT). No. of bitstreams: 1 2-s2.0-21744437588.pdf: 153185 bytes, checksum: 41c4ab29f562a25fdeca3750908c9d0a (MD5) Previous issue date: 2005en
dc.description.provenanceMade available in DSpace on 2015-11-26T14:09:09Z (GMT). No. of bitstreams: 2 2-s2.0-21744437588.pdf: 153185 bytes, checksum: 41c4ab29f562a25fdeca3750908c9d0a (MD5) 2-s2.0-21744437588.pdf.txt: 22659 bytes, checksum: 048a51ec76338ec8b60b0ab83c4c728f (MD5) Previous issue date: 2005en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/93758
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/93758-
dc.identifier.idScopus2-s2.0-21744437588pt_BR
dc.description.referenceAppleton, R.E., West syndrome: Long-term prognosis and social aspects (2001) Brain Dev, 23, pp. 688-691pt_BR
dc.description.referenceMitchell, W.G., Shah, N.S., Vigabatrin for infantile spasms (2002) Pediatr Neurol, 27, pp. 161-164pt_BR
dc.description.referenceWallace, S.J., Newer antiepileptic drugs: Advantages and disadvantages (2001) Brain & Dev, 23, pp. 277-283pt_BR
dc.description.referenceHarding, G.F., Wild, J.M., Robertson, K.A., Rietbrock, S., Martinez, C., Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss (2000) Neurology, 55, pp. 347-352pt_BR
dc.description.referenceMcDonagh, J., Stephen, L.J., Dolan, F.M., Peripheral retinal dysfunction in patients taking vigabatrin (2003) Neurology, 61, pp. 1690-1694pt_BR
dc.description.referenceChiron, C., Dulac, O., Luna, D., Vigabatrin in infantile spasms (1990) Lancet, 335, pp. 363-364pt_BR
dc.description.referenceChiron, C., Dulac, O., Beaumont, D., Palacios, L., Pajot, N., Mumford, J., Therapeutic trial of vigabatrin in refractory infantile spasms (1991) J Child Neurol, (SUPPL. 2), pp. S52-S59pt_BR
dc.description.referenceRotta, N.T., Silva, A.R., Ohlweiler, L., Riesgo, R., Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis (2003) Arq Neuropsiquiatr, 61, pp. 988-990pt_BR
dc.description.referenceCuratolo, P., Seri, S., Verdecchia, M., Bombardieri, R., Infantile spasms in tuberous sclerosis complex (2001) Brain Dev, 23, pp. 502-507pt_BR
dc.description.referenceElterman, R.D., Shields, W.D., Mansdield, K.A., Nakagawa, J., Randomized trial of vigabatrin in patients with infantile spasms (2001) Neurology, 57, pp. 1416-1421pt_BR
dc.description.referenceRiikonen, R.S., Steroids or vigabatrin in the treatment of infantile spasms? (2000) Pediatr Neurol, 23, pp. 403-408pt_BR
dc.description.referenceAntoniuk, S.A., Bruck, I., Spessatto, A., West syndrome: Clinical and electroencephalographic follow up of 70 patients and response to its treatment with adrenocorticotropic hormone, prednisone, vigabatrin, nitrazepam and valproate (2000) Arq Neuropsiquiatr, 58, pp. 683-690pt_BR
dc.description.referenceFejerman, N., Cersosimo, R., Caraballo, R., Vigabatrin as a first-choice drug in the treatment of West syndrome (2000) J Child Neurol, 15, pp. 161-165pt_BR
dc.description.referenceAppleton, R.E., Peters, A.C., Mumford, J.P., Shaw, D.E., Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms (1999) Epilepsia, 40, pp. 1627-1633pt_BR
dc.description.referenceGranstrom, M.I., Gaily, E., Liukkonen, E., Treatment of infantile spasms of a population-based study with vigabatrin as the first drug for spasms (1999) Epilepsia, 40, pp. 950-957pt_BR
dc.description.referenceCossette, P., Riviello, J.J., Carmant, L., ACTH versus vigabatrin therapy in infantile spasms: A retrospective study (1999) Neurology, 52, pp. 1691-1694pt_BR
dc.description.referenceVilleneuve, N., Soufflet, C., Plouin, P., Chiron, C., Dulac, O., Treatment of infantile spasms with vigabatrin as first-line therapy and in monoteraphy: Apropos of 70 infants (1998) Arch Pediatr, 5, pp. 731-738pt_BR
dc.description.referenceWohlrab, G., Boltshauser, E., Schmitt, B., Vigabatrin as a first-line drug in West syndrome: Clinical and electroencephalographic outcome (1998) Neuropediatrics, 29, pp. 133-136pt_BR
dc.description.referenceVigevano, F., Cilio, M.R., Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study (1997) Epilepsia, 38, pp. 1270-1274pt_BR
dc.description.referenceArndt, C.F., Derambure, P., Defoort-Dhellemmes, S., Hache, J.C., Outer retinal dysfunction in patients with vigabatrin (1990) Neurology, 52, pp. 1201-1205pt_BR
dc.description.referenceKrauss, G.L., Johnson, M.A., Miller, N.R., Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings (1998) Neurology, 50, pp. 614-618pt_BR
dc.description.referenceBanin, E., Shalev, R.S., Obolensky, A., Neis, R., Chowers, I., Gross-Tsur, V., Retinal function abnormalities in patients treated with vigabatrin (2003) Arch Ophthalmol, 121, pp. 811-816pt_BR
dc.description.referenceHarding, G.F., Wild, J.M., Robertson, K.A., Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction (2000) Epilepsia, 41, pp. 1420-1431pt_BR
dc.description.referenceMalmgren, K., Ben-Menachem, E., Frisen, L., Vigabatrin visual toxicity: Evolution and dose dependence (2001) Epilepsia, 42, pp. 609-615pt_BR
dc.description.referenceHardus, P., Verduin, W.M., Engelsman, M., Visual field loss associated with vigabatrin: Quantification and relation to dosage (2001) Epilepsia, 42, pp. 262-267pt_BR
dc.description.referenceJensen, H., Sjo, O., Uldall, P., Vigabatrin and retinal changes (2002) Doc Ophthalmol, 104, pp. 171-180pt_BR
dc.description.referenceSchmitz, B., Schmidt, T., Jokiel, B., Pfeiffer, S., Tiel-Wilck, K., Ruther, K., Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study (2002) J Neurol, 249, pp. 469-475pt_BR
dc.description.referenceCapovilla, G., Beccaria, F., Montagnini, A., Short-term nonhormonal and nonsteroid treatment in West syndrome (2003) Epilepsia, 44, pp. 1085-1088pt_BR
dc.description.referenceKoul, R., Chacko, A., Ganesh, A., Bulusu, S., Al Riyami, K., Vigabatrin associated retinal dysfunction in children with epilepsy (2001) Arch Dis Child, 85, pp. 469-473pt_BR
dc.description.referenceSchmidt, T., Ruther, K., Jokiel, B., Pfeiffer, S., Tiel-Wilck, Schmitz, B., Is visual field constriction in patients treated with vigabatrin reversible? (2002) J Neurol, 249, pp. 1066-1071pt_BR
dc.description.referenceGiordano, L., Valseriati, D., Vignoli, A., Morescalchi, F., Gandolfo, E., Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: Is young age a favorable factor? (2000) Neurol Sci, 21, pp. 185-186pt_BR
dc.description.referenceVersino, M., Veggiotti, P., Reversibility of vigabatrin-induced visual-field defect (1999) The Lancet, 354, p. 486pt_BR
dc.description.referenceVanhatalo, S., Alen, R., Riikonen, R., Reversed visual field constrictions in children after vigabatrin withdrawal - True retinal recovery or improved test performance only? (2001) Seizure, 10, pp. 508-511pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-21744437588.pdf149.59 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.